Celea Therapeutics emerged from stealth this week with $180 million in debut financing, one of the largest first-round raises in biotech so far in 2026, to advance a candidate for idiopathic pulmonary fibrosis (IPF) into a head-to-head Phase 3 trial against pirfenidone, one of only two antifibrotic therapies currently approved for the disease. The round was led by RA Capital Management, with participation from Leaps by Bayer, PureTech Health and a syndicate of additional life sciences investors that the company did not fully disclose.

IPF is a progressive scarring disease of the lungs with a median survival of three to five years from diagnosis, and treatment options have remained largely static since pirfenidone and nintedanib received approval more than a decade ago. Both drugs slow the rate of lung function decline but do not reverse fibrosis, and their tolerability profiles, marked by gastrointestinal side effects and photosensitivity for pirfenidone and diarrhea for nintedanib, contribute to real-world discontinuation rates that specialists have long flagged as a gap the field has struggled to close.

Celea has not disclosed the mechanism of action of its lead candidate in detail, saying only that the molecule targets a distinct fibrotic signaling pathway from the two approved antifibrotics and is designed to be dosed once daily with a more favorable tolerability profile in early studies. The company said the planned Phase 3 trial, expected to begin patient enrollment in the third quarter of 2026, will be designed as a direct comparator study against pirfenidone rather than a placebo-controlled trial, a design choice that reflects both the availability of an approved standard of care and investor appetite for a program that can generate comparative effectiveness data useful for payer negotiations from the outset.

The financing lands amid a broader rebound in biotech dealmaking and venture funding in 2026, with global biotech M&A on pace for its strongest year since before the pandemic as large pharmaceutical companies facing patent cliffs compete for a shrinking pool of late-stage assets. Debut financings of this size remain relatively rare, reflecting investor selectivity even as overall capital deployment into the sector has increased; RA Capital and Bayer’s venture arm have both been particularly active in respiratory and fibrotic disease investing over the past two years, viewing IPF as a category with clear unmet need and a defined regulatory pathway.

Celea’s executive team includes veterans of prior fibrosis-focused biotechs, though the company has not yet named a permanent chief executive, operating instead under an interim leadership structure while it builds out its clinical operations team ahead of the Phase 3 start. The company said it expects the new funding to support operations into a Phase 3 interim readout, without specifying a timeline.